MARKET
IPO

INAB

IN8BIO, INC.
INAB
NASDAQ
Upcoming IPOs
Expected Listing Date: 2020-11-13
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-55.87~-49.29
-
348.84~395.35
291.46M~330.32M
Biotechnology & Medical Research
2020-10-16
Public Filing
View Prospectus
Pending
Offering
Price Range: 15.00~17.00
Shares to be Issued: 4687.50K
2020-11-11
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 19.43M
2020-11-13
Listed
News
Financial
Releases
Corp Actions
Analysis
Profile
No Data
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INAB. Analyze the recent business situations of IN8BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
President/Chief Executive Officer/Director/Primary Contact
William Ho
Co-Founder/Executive Vice President/Chief Scientific Officer
Lawrence Lamb
Vice President - Operations
Melissa Beelen
Director
Thomas Cirrito
Director
Travis Whitfill
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About INAB
IN8bio, Inc. is clinical-stage biotechnology company. The Company is focused on developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Its product candidate includes INB-200 and INB-100. INB-200 is genetically modified autologous gamma-delta T cell product candidate that the Company is developing for the treatment of solid tumors. Its indication for INB-200 is glioblastoma (GBM). INB-100 is its allogeneic product candidate that is developed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). The Company is also developing a portfolio of preclinical programs. INB-400 is its preclinical program focused on developing allogeneic cellular therapies for solid tumor cancers and INB-300 is the preclinical program focused on developing product candidates based on gamma-delta T cells with an added chimeric antigen receptor (CAR).
More

Webull offers kinds of IN8BIO, INC. stock information, including NASDAQ:INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.